Chris Cuomo Admits to Taking Ivermectin for Long Covid

Chris Cuomo Admits to Taking Ivermectin for Long Covid


Former CNN anchor Chris Cuomo disclosed that he is undergoing treatment for his “long Covid” diagnosis using the pharmaceutical drug Ivermectin, despite his previous criticism of those who advocated for the drug in 2020, suggesting they “need to be shamed.”

Cuomo, now employed by NewsNation, made the revelation during an appearance on Patrick Bet-David’s podcast “PBD.”

While he maintained his earlier stance on Covid treatments that differed from the vaccine, Cuomo asserted that the US government’s guidance on Ivermectin “was wrong” and that his initial analysis was based on purported facts provided by the government at the time.

“My doctors have diagnosed me with ‘Long Covid,'” he stated, later mentioning,  “I’m doing all the protocols”

Cuomo defended his past statements, attributing them to the information available from the government at the time. However, he admitted to currently taking a regular dose of Ivermectin.

“Ivermectin was a boogeyman early on in COVID. That was wrong. We were given bad information about Ivermectin,” he continued.

Cuomo questioned why there was misinformation surrounding Ivermectin, asserting that the clinical community knew it was safe.

“The real question is why?… The entire clinical community knew that Ivermectin couldn’t hurt you. They knew it, Patrick. I know they knew it. How did I know it? Because now I am doing nothing but talking to these clinicians who at the time were overwhelmed but they weren’t saying anything, not that they were hiding anything. But it’s cheap, it’s not owned by anybody and it’s used as anti-microbial and an anti-viral in all these different ways and has been for a long time,” said Cuomo.

Cuomo revealed that his doctor and her family had been taking Ivermectin during the pandemic and found it effective. He acknowledged that there was undue fear surrounding its use and admitted to reporting on it differently now that he possesses more information.


Poll

Join the Newsletter